XML 48 R35.htm IDEA: XBRL DOCUMENT v3.4.0.3
Segment and Other Revenue Information (Tables)
 3 Months Ended
Apr. 03, 2016
Segment Reporting [Abstract]  
Schedule of Selected Income Statement Information by Segment
Selected Statement of Income Information
 
 
Earnings
 
Depreciation and Amortization(a)
 
 
April 3,

 
March 29,

 
April 3,

 
March 29,

(MILLIONS OF DOLLARS)
 
2016

 
2015

 
2016

 
2015

Three months ended
 
 
 
 
 
 
 
 
U.S.
 
 
 
 
 
 
 
 
Revenue
 
$
582

 
$
521

 
 
 
 
Cost of Sales
 
131

 
125

 
 
 
 
Gross Profit
 
451

 
396

 
 
 
 
    Gross Margin
 
77.5
%
 
76.0
%
 
 
 
 
Operating Expenses
 
92

 
81

 
 
 
 
Other (income)/deductions
 
—

 
—

 
 
 
 
U.S. Earnings
 
359

 
315

 
$
6

 
$
6

 
 
 
 
 
 
 
 
 
International
 
 
 
 
 
 
 
 
Revenue(b)
 
567

 
571

 
 
 
 
Cost of Sales
 
196

 
204

 
 
 
 
Gross Profit
 
371

 
367

 
 
 
 
    Gross Margin
 
65.4
%
 
64.3
%
 
 
 
 
Operating Expenses
 
109

 
135

 
 
 
 
Other (income)/deductions
 
2

 
2

 
 
 
 
International Earnings
 
260

 
230

 
11

 
11

 
 
 
 
 
 
 
 
 
Total operating segments
 
619

 
545

 
17

 
17

 
 
 
 
 
 
 
 
 
Other business activities
 
(74
)
 
(68
)
 
6

 
7

Reconciling Items:
 
 
 
 
 
 
 
 
Corporate
 
(169
)
 
(131
)
 
10

 
9

Purchase accounting adjustments
 
(26
)
 
(13
)
 
22

 
13

Acquisition-related costs
 
(1
)
 
(1
)
 
—

 
—

Certain significant items(c)
 
13

 
(41
)
 
1

 
1

Other unallocated
 
(30
)
 
(61
)
 
1

 
1

Total Earnings(d)
 
$
332

 
$
230

 
$
57

 
$
48

(a) 
Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b) 
Revenue denominated in euros was $154 million and $135 million for the three months ended April 3, 2016, and March 29, 2015, respectively.
(c) 
For the three months ended April 3, 2016, Certain significant items primarily includes: (i) Zoetis stand-up costs of $12 million; (ii) a net gain related to the sale of certain manufacturing sites and products of $33 million related to our operational efficiency initiative, partially offset by restructuring charges of $2 million and consulting fees of $3 million related to our operational efficiency initiative; and (iii) charges related to the supply network strategy of $3 million.
For the three months ended March 29, 2015, Certain significant items primarily includes: (i) Zoetis stand-up costs of $23 million; (ii) consulting fees related to our operational efficiency initiative and supply network strategy of $15 million; and (iii) charges due to unusual investor-related activities of $3 million.
(d) 
Defined as income before provision for taxes on income.
Schedule of Significant Product Revenues
Revenue by Species
Species revenue are as follows:
 
 
Three Months Ended
 
 
April 3,

 
March 29,

(MILLIONS OF DOLLARS)
 
2016

 
2015

Livestock:
 
 
 
 
Cattle
 
$
377

 
$
397

Swine
 
146

 
170

Poultry
 
122

 
129

Fish
 
17

 
—

Other
 
21

 
19

 
 
683

 
715

Companion Animal:
 
 
 
 
Horses
 
39

 
40

Dogs and Cats
 
427

 
337

 
 
466

 
377

 
 
 
 
 
Contract Manufacturing
 
13

 
10

 
 
 
 
 
Total revenue
 
$
1,162

 
$
1,102

Revenue by Major Product Category
Revenue by major product category are as follows:
 
 
Three Months Ended
 
 
April 3,

 
March 29,

(MILLIONS OF DOLLARS)
 
2016

 
2015

Anti-infectives
 
$
291

 
$
312

Vaccines
 
301

 
271

Parasiticides
 
145

 
153

Medicated feed additives
 
138

 
121

Other pharmaceuticals
 
221

 
187

Other non-pharmaceuticals
 
53

 
48

Contract manufacturing
 
13

 
10

Total revenue
 
$
1,162

 
$
1,102